These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 18438841

  • 1. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P.
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [Abstract] [Full Text] [Related]

  • 2. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
    Marotte H, Maslinski W, Miossec P.
    Arthritis Res Ther; 2005 May; 7(1):R149-55. PubMed ID: 15642135
    [Abstract] [Full Text] [Related]

  • 3. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP, Liljeström M, Laiho K, Tiitinen S, Kaarela K, Hurme M.
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [Abstract] [Full Text] [Related]

  • 4. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D.
    Arthritis Rheum; 2003 Jul; 48(7):1849-52. PubMed ID: 12847678
    [Abstract] [Full Text] [Related]

  • 5. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
    Ulfgren AK, Andersson U, Engström M, Klareskog L, Maini RN, Taylor PC.
    Arthritis Rheum; 2000 Nov; 43(11):2391-6. PubMed ID: 11083259
    [Abstract] [Full Text] [Related]

  • 6. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 7. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N.
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [Abstract] [Full Text] [Related]

  • 8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 9. Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis.
    Sugihara M, Tsutsumi A, Suzuki E, Wakamatsu E, Suzuki T, Ogishima H, Hayashi T, Chino Y, Ishii W, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T.
    Arthritis Rheum; 2007 Jul; 56(7):2160-9. PubMed ID: 17599736
    [Abstract] [Full Text] [Related]

  • 10. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN.
    Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484
    [Abstract] [Full Text] [Related]

  • 11. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids.
    de Paz B, Alperi-López M, Ballina-García FJ, Prado C, Mozo L, Gutiérrez C, Suárez A.
    J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912
    [Abstract] [Full Text] [Related]

  • 12. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
    Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Pérez C, Aguirre A, Salazar-Onfray F, Aguillón JC.
    Scand J Rheumatol; 2004 Mar; 33(4):228-32. PubMed ID: 15370717
    [Abstract] [Full Text] [Related]

  • 13. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, Skogh T.
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [Abstract] [Full Text] [Related]

  • 14. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 15. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, Mattei JP, Nogueira L, Mugnier B, Legeron P, Landt O, Serre G, Roudier J, Roudier C.
    Arthritis Rheum; 2007 Dec 15; 57(8):1426-30. PubMed ID: 18050183
    [Abstract] [Full Text] [Related]

  • 16. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.
    Arthritis Rheum; 2008 Aug 15; 58(8):2257-67. PubMed ID: 18668547
    [Abstract] [Full Text] [Related]

  • 17. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Aug 15; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 18. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar 15; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 19. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A, Arnaud B, Marrote H, Cazalis MA, Diasparra J, Gouraud A, Mougin B, Miossec P.
    J Rheumatol; 2007 Nov 15; 34(11):2158-61. PubMed ID: 17896807
    [Abstract] [Full Text] [Related]

  • 20. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan 15; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.